keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer genomic

keyword
https://www.readbyqxmd.com/read/28213802/high-expression-of-aspm-correlates-with-tumor-progression-and-predicts-poor-outcome-in-patients-with-prostate-cancer
#1
Jian-Jiang Xie, Yang-Jia Zhuo, Yu Zheng, Ru-Jun Mo, Ze-Zhen Liu, Bo-Wei Li, Zhi-Duan Cai, Xue-Jin Zhu, Yu-Xiang Liang, Hui-Chan He, Wei-de Zhong
PURPOSE: Abnormal spindle microtubule assembly (ASPM) gene was known to be linked with poor clinical prognosis in various tumors. However, the clinical significance of ASPM in prostate cancer (PCa) has not yet been understood. The purpose of this study was to determine the association of ASPM with tumor progression and prognosis in PCa patients. METHODS: The expression of ASPM at protein level in human PCa and non-cancerous prostate tissue was detected by immunohistochemical analysis, which was further validated by using microarray-based dataset (NCBI GEO: GSE21032 and The Cancer Genome Atlas (TCGA) dataset) at mRNA level...
February 17, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28212531/msmb-gene-rs10993994-polymorphism-increases-the-risk-of-prostate-cancer
#2
Tao Peng, Lifeng Zhang, Lijie Zhu, Yuan-Yuan Mi
Genome-wide association studies (GWASs) identified microseminoprotein-β (MSMB) gene rs10993994 polymorphism was significantly associated with prostate cancer (PC) risk. However, the association between MSMB gene rs10993994 polymorphism and PC risk remains controversial. Therefore, we performed a systematic review and meta-analysis by searching in the databases of PubMed, and Embase. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by using fixed-effect or random-effect models. A total of 11 publications containing 13 case-control studies for rs10993994 polymorphism were included in our analysis...
February 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28208518/re-genomic-alterations-in-cell-free-dna-and-enzalutamide-resistance-in-castration-resistant-prostate-cancer
#3
Samir S Taneja
No abstract text is available yet for this article.
March 2017: Journal of Urology
https://www.readbyqxmd.com/read/28202223/filtration-based-enrichment-of-circulating-tumor-cells-from-all-prostate-cancer-risk-groups
#4
Julius Adebayo Awe, Jeff Saranchuk, Darrel Drachenberg, Sabine Mai
OBJECTIVE: To combine circulating tumor cell (CTC) isolation by filtration and immunohistochemistry to investigate the presence of CTCs in low, intermediate, and high-risk prostate cancer (PCa). CTCs isolated from these risk groups stained positive for both cytokeratin and androgen receptors, but negative for CD45. PATIENTS AND METHODS: Blood samples from 41 biopsy confirmed patients with PCa at different clinical stages such as low, intermediate, and high risk were analyzed...
February 12, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28188816/a-chemical-genomics-approach-to-drug-reprofiling-in-oncology-antipsychotic-drug-risperidone-as-a-potential-adenocarcinoma-treatment
#5
Suzanne J Dilly, Andrew J Clark, Andrew Marsh, Daniel A Mitchell, Ricky Cain, Colin W G Fishwick, Paul C Taylor
Drug reprofiling is emerging as an effective paradigm for discovery of cancer treatments. Herein, an antipsychotic drug is immobilised using the Magic Tag(®) chemical genomics tool and screened against a T7 bacteriophage displayed library of polypeptides from Drosophila melanogaster, as a whole genome model, to uncover an interaction with a section of 17-β-HSD10, a proposed prostate cancer target. A computational study and enzyme inhibition assay with full length human 17-β-HSD10 identifies risperidone as a drug reprofiling candidate...
February 8, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28188414/a-potential-panel-of-four-long-noncoding-rna-signature-in-prostate-cancer-predicts-biochemical-recurrence-free-survival-and-disease-free-survival
#6
Tian-Bao Huang, Chuan-Peng Dong, Guang-Chen Zhou, Sheng-Ming Lu, Yang Luan, Xiao Gu, Lei Liu, Xue-Fei Ding
PURPOSES: Growing evidences showed that lncRNAs abnormally expressed in cancer tissues and played irreplaceable roles in tumorigenesis, progression and metastasis. In present study, we aimed to identify lncRNA expression signature that can predict biochemical recurrence-free (BCR-free) survival of prostate cancer (PCa) patients. METHODS: A total of 291 patients with pathologic confirmed PCa in The Cancer Genome Atlas dataset were recruited and included. With the specific risk score formula, patients were further classified into high-risk group and low-risk group...
February 10, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28187449/low-pca3-expression-is-a-marker-of-poor-differentiation-in-localized-prostate-tumors-exploratory-analysis-from-12-076-patients
#7
Mohammed Alshalalfa, Gerald W Verhaegh, Ewan A Gibb, Maria Santiago-Jiménez, Nicholas Erho, Jennifer Jordan, Kasra Yousefi, Lucia L C Lam, Tyler Kolisnik, Jijumon Chelissery, Roland Seiler, Ashley E Ross, R Jeffrey Karnes, Edward M Schaeffer, Tamara T Lotan, Robert B Den, Stephen J Freedland, Elai Davicioni, Eric A Klein, Jack A Schalken
BACKGROUND: Prostate cancer antigen 3 (PCA3) is a prostate cancer diagnostic biomarker that has been clinically validated. The limitations of the diagnostic role of PCA3 in initial biopsy and the prognostic role are not well established. Here, we elucidate the limitations of tissue PCA3 to predict high grade tumors in initial biopsy. RESULTS: PCA3 has a bimodal distribution in both biopsy and radical prostatectomy (RP) tissues, where low PCA3 expression was significantly associated with high grade disease (p<0...
February 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28166537/synthetic-essentiality-of-chromatin-remodelling-factor-chd1-in-pten-deficient-cancer
#8
Di Zhao, Xin Lu, Guocan Wang, Zhengdao Lan, Wenting Liao, Jun Li, Xin Liang, Jasper Robin Chen, Sagar Shah, Xiaoying Shang, Ming Tang, Pingna Deng, Prasenjit Dey, Deepavali Chakravarti, Peiwen Chen, Denise J Spring, Nora M Navone, Patricia Troncoso, Jianhua Zhang, Y Alan Wang, Ronald A DePinho
Synthetic lethality and collateral lethality are two well-validated conceptual strategies for identifying therapeutic targets in cancers with tumour-suppressor gene deletions. Here, we explore an approach to identify potential synthetic-lethal interactions by screening mutually exclusive deletion patterns in cancer genomes. We sought to identify 'synthetic-essential' genes: those that are occasionally deleted in some cancers but are almost always retained in the context of a specific tumour-suppressor deficiency...
February 6, 2017: Nature
https://www.readbyqxmd.com/read/28163245/anti-androgen-2-hydroxyflutamide-modulates-cadherin-catenin-and-androgen-receptor-phosphorylation-in-androgen-sensitive-lncap-and-androgen-independent-pc3-prostate-cancer-cell-lines-acting-via-pi3k-akt-and-mapk-erk1-2-pathways
#9
Ewelina Górowska-Wójtowicz, Anna Hejmej, Alicja Kamińska, Laura Pardyak, Małgorzata Kotula-Balak, Joanna Dulińska-Litewka, Piotr Laidler, Barbara Bilińska
This study aimed to investigate rapid effect of anti-androgen 2-hydroxyflutamide (HF) on cadherin/catenin complex and androgen receptor (AR) phosphorylation in prostate cancer cell lines. In addition, a role of PI3K/Akt and MAPK/ERK1/2 pathways in mediating these effects was explored. We have demonstrated that in androgen-sensitive LNCaP cells HF induced rapid increase of E-cadherin phosphorylation at Ser 838/840 (p<0.05) in MAPK/ERK1/2-dependent manner, whereas phosphorylation of β-catenin at Tyr 654 was unchanged...
February 2, 2017: Toxicology in Vitro: An International Journal Published in Association with BIBRA
https://www.readbyqxmd.com/read/28157696/resveratrol-induces-mitochondria-mediated-caspase-independent-apoptosis-in-murine-prostate-cancer-cells
#10
Sanjay Kumar, Erdal Eroglu, James A Stokes, Karyn Scissum-Gunn, Sabita N Saldanha, Udai P Singh, Upender Manne, Selvarangan Ponnazhagan, Manoj K Mishra
Found in the skins of red fruits, including grapes, resveratrol (RES) is a polyphenolic compound with cancer chemopreventive activity. Because of this activity, it has gained interest for scientific investigations. RES inhibits tumor growth and progression by targeting mitochondria-dependent or -independent pathways. However, further investigations are needed to explore the underlying mechanisms.The present study is focused on examining the role of RES-induced, mitochondria-mediated, caspase-independent apoptosis of prostate cancer cells, namely transgenic adenocarcinoma of mouse prostate (TRAMP) cells...
February 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28156002/lucap-prostate-cancer-patient-derived-xenografts-reflect-the-molecular-heterogeneity-of-advanced-disease-an-d-serve-as-models-for-evaluating-cancer-therapeutics
#11
Holly M Nguyen, Robert L Vessella, Colm Morrissey, Lisha G Brown, Ilsa M Coleman, Celestia S Higano, Elahe A Mostaghel, Xiaotun Zhang, Lawrence D True, Hung-Ming Lam, Martine Roudier, Paul H Lange, Peter S Nelson, Eva Corey
BACKGROUND: Metastatic prostate cancer is a common and lethal disease for which there are no therapies that produce cures or long-term durable remissions. Clinically relevant preclinical models are needed to increase our understanding of biology of this malignancy and to evaluate new agents that might provide effective treatment. Our objective was to establish and characterize patient-derived xenografts (PDXs) from advanced prostate cancer (PC) for investigation of biology and evaluation of new treatment modalities...
February 3, 2017: Prostate
https://www.readbyqxmd.com/read/28148485/prostate-cancer-recurrence-genomic-clues
#12
(no author information available yet)
In the largest genomic analysis of intermediate-risk prostate cancer samples to date, researchers have uncovered a five-element molecular signature that could help pinpoint patients whose disease is likely to recur and metastasize even after surgery or radiotherapy. They hope to develop a prognostic assay from this signature that can be used in the clinic.
February 1, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28144969/high-levels-of-the-ar-v7-splice-variant-and-co-amplification-of-the-golgi-protein-coding-yipf6-in-ar-amplified-prostate-cancer-bone-metastases
#13
Erik Djusberg, Emma Jernberg, Elin Thysell, Irina Golovleva, Pia Lundberg, Sead Crnalic, Anders Widmark, Anders Bergh, Maria Brattsand, Pernilla Wikström
BACKGROUND: The relation between androgen receptor (AR) gene amplification and other mechanisms behind castration-resistant prostate cancer (CRPC), such as expression of constitutively active AR variants and steroid-converting enzymes has been poorly examined. Specific aim was to examine AR amplification in PC bone metastases and to explore molecular and functional consequences of this, with the long-term goal of identifying novel molecular targets for treatment. METHODS: Gene amplification was assessed by fluorescence in situ hybridization in cryo-sections of clinical PC bone metastases (n = 40) and by PCR-based copy number variation analysis...
February 1, 2017: Prostate
https://www.readbyqxmd.com/read/28144231/non-genomic-actions-of-the-androgen-receptor-in-prostate-cancer
#14
REVIEW
Jacky K Leung, Marianne D Sadar
Androgen receptor (AR) is a validated drug target for prostate cancer based on its role in proliferation, survival, and metastases of prostate cancer cells. Unfortunately, despite recent improvements to androgen deprivation therapy and the advent of better antiandrogens with a superior affinity for the AR ligand-binding domain (LBD), most patients with recurrent disease will eventually develop lethal metastatic castration-resistant prostate cancer (CRPC). Expression of constitutively active AR splice variants that lack the LBD contribute toward therapeutic resistance by bypassing androgen blockade and antiandrogens...
2017: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/28143998/correction-genomic-deletion-of-chromosome-12p-is-an-independent-prognostic-marker-in-prostate-cancer
#15
Martina Kluth, Ramin Ahrary, Claudia Hube-Magg, Malik Ahmed, Heinke Volta, Catina Schwemin, Stefan Steurer, Corinna Wittmer, Waldemar Wilczak, Eike Burandt, Till Krech, Meike Adam, Uwe Michl, Hans Heinzer, Georg Salomon, Markus Graefen, Christina Koop, Sarah Minner, Ronald Simon, Guido Sauter, Thorsten Schlomm
No abstract text is available yet for this article.
January 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28140459/transcriptome-evaluation-of-the-relation-between-body-mass-index-and-prostate-cancer-outcomes
#16
Hyun Kim, Ingrid Kalchman, María Santiago-Jiménez, Jonathan Lehrer, Jenny Guo, Gretchen Hermann, Kosj Yamoah, Mohammed Alshalalfa, Huei-Chung Huang, Ashley E Ross, Edward M Schaeffer, Elai Davicioni, Nicholas Erho, Kasra Yousefi, Robert B Den
BACKGROUND: Large epidemiological studies indicate that an increased body mass index (BMI) is associated with increased prostate cancer (PCa) mortality. Data indicate that there is no association between elevated metabolic pathway proteins and PCa mortality. There are no published studies evaluating the relation between BMI and metabolic pathways with respect to PCa outcomes with a genomics approach. METHODS: The Decipher Genomic Resource Information Database was queried for patients who had undergone prostatectomy and had BMI information available...
January 31, 2017: Cancer
https://www.readbyqxmd.com/read/28139693/genome-wide-association-study-of-prostate-specific-antigen-levels-identifies-novel-loci-independent-of-prostate-cancer
#17
Thomas J Hoffmann, Michael N Passarelli, Rebecca E Graff, Nima C Emami, Lori C Sakoda, Eric Jorgenson, Laurel A Habel, Jun Shan, Dilrini K Ranatunga, Charles P Quesenberry, Chun R Chao, Nirupa R Ghai, David Aaronson, Joseph Presti, Tobias Nordström, Zhaoming Wang, Sonja I Berndt, Stephen J Chanock, Jonathan D Mosley, Robert J Klein, Mridu Middha, Hans Lilja, Olle Melander, Mark N Kvale, Pui-Yan Kwok, Catherine Schaefer, Neil Risch, Stephen K Van Den Eeden, John S Witte
Prostate-specific antigen (PSA) levels have been used for detection and surveillance of prostate cancer (PCa). However, factors other than PCa-such as genetics-can impact PSA. Here we present findings from a genome-wide association study (GWAS) of PSA in 28,503 Kaiser Permanente whites and 17,428 men from replication cohorts. We detect 40 genome-wide significant (P<5 × 10(-8)) single-nucleotide polymorphisms (SNPs): 19 novel, 15 previously identified for PSA (14 of which were also PCa-associated), and 6 previously identified for PCa only...
January 31, 2017: Nature Communications
https://www.readbyqxmd.com/read/28139641/reconstructing-metastatic-seeding-patterns-of-human-cancers
#18
Johannes G Reiter, Alvin P Makohon-Moore, Jeffrey M Gerold, Ivana Bozic, Krishnendu Chatterjee, Christine A Iacobuzio-Donahue, Bert Vogelstein, Martin A Nowak
Reconstructing the evolutionary history of metastases is critical for understanding their basic biological principles and has profound clinical implications. Genome-wide sequencing data has enabled modern phylogenomic methods to accurately dissect subclones and their phylogenies from noisy and impure bulk tumour samples at unprecedented depth. However, existing methods are not designed to infer metastatic seeding patterns. Here we develop a tool, called Treeomics, to reconstruct the phylogeny of metastases and map subclones to their anatomic locations...
January 31, 2017: Nature Communications
https://www.readbyqxmd.com/read/28134791/a-tale-of-two-signals-ar-and-wnt-in-development-and-tumorigenesis-of-prostate-and-mammary-gland
#19
REVIEW
Hubert Pakula, Dongxi Xiang, Zhe Li
Prostate cancer (PCa) is one of the most common cancers and among the leading causes of cancer deaths for men in industrialized countries. It has long been recognized that the prostate is an androgen-dependent organ and PCa is an androgen-dependent disease. Androgen action is mediated by the androgen receptor (AR). Androgen deprivation therapy (ADT) is the standard treatment for metastatic PCa. However, almost all advanced PCa cases progress to castration-resistant prostate cancer (CRPC) after a period of ADT...
January 27, 2017: Cancers
https://www.readbyqxmd.com/read/28131897/long-noncoding-rnas-and-sulforaphane-a-target-for-chemoprevention-and-suppression-of-prostate-cancer
#20
Laura M Beaver, Rachael Kuintzle, Alex Buchanan, Michelle W Wiley, Sarah T Glasser, Carmen P Wong, Gavin S Johnson, Jeff H Chang, Christiane V Löhr, David E Williams, Roderick H Dashwood, David A Hendrix, Emily Ho
Long noncoding RNAs (lncRNAs) have emerged as important in cancer development and progression. The impact of diet on lncRNA expression is largely unknown. Sulforaphane (SFN), obtained from vegetables like broccoli, can prevent and suppress cancer formation. Here we tested the hypothesis that SFN attenuates the expression of cancer-associated lncRNAs. We analyzed whole-genome RNA-sequencing data of normal human prostate epithelial cells and prostate cancer cells treated with 15 μM SFN or dimethylsulfoxide. SFN significantly altered expression of ~100 lncRNAs in each cell type and normalized the expression of some lncRNAs that were differentially expressed in cancer cells...
January 12, 2017: Journal of Nutritional Biochemistry
keyword
keyword
96305
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"